Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.ZIOP · Entity 8339 | SVP, Treasurer & CAO | January 08, 2021 | January 12, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date January 08, 2021 · Filed January 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,965 |
Reported balance
After 2021-01-08 transaction · row 1
1 source rowRow 1 · 2021-01-08 · Sale · Disposed 18,020 · Balance 63,965 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 08, 2021 Filed Jan 12, 2021 21:34 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | SaleCommon Stock | 18,020 | $3.09 | $55,681.80 |
DisclosureSEC source: 0001209191-21-003244 · doc4.xml · nonDerivative · entry 1 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,965 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:50 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005785 · doc4.xml · nonDerivative · entry 1 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,985 F1 · shares: 6,000 shares shall vest on each of 12/31/2020, 12/31/2021 and 12/31/2022. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:09 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | SaleCommon Stock | 21,570 | $4.55 | $98,143.50 |
DisclosureSEC source: 0001209191-20-001176 · doc4.xml · nonDerivative · entry 1 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,985 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:09 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 48,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001209191-20-001176 · doc4.xml · derivative · entry 2 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2029-12-31 F3 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2019. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 22:07 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 11,667 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001209191-19-058365 · doc4.xml · derivative · entry 3 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,667 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 22:07 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | SaleCommon Stock | 11,667 | $5.25 | $61,251.75 |
DisclosureSEC source: 0001209191-19-058365 · doc4.xml · nonDerivative · entry 2 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,555 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2019. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 22:07 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Exercise / conversionCommon Stock | 11,667 | $2.85 | $33,250.95 |
DisclosureSEC source: 0001209191-19-058365 · doc4.xml · nonDerivative · entry 1 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:27 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 58,536 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001209191-19-002787 · doc4.xml · derivative · entry 2 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,536 Underlying: Common Stock · 58,536 shares Expires 2029-01-06 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2018. Read SEC document |
| January 06, 2019 Filed Jan 8, 2019 21:27 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 37,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002787 · doc4.xml · nonDerivative · entry 1 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,555 F1 · shares: 12,374 shares shall vest on each of 12/31/2019, 12/31/2020 and 12/31/2021. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 02:16 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 9,334 | $1.87 | $17,454.58 |
DisclosureSEC source: 0001209191-19-000588 · doc4.xml · nonDerivative · entry 3 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,433 F1 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 30, 2018 Filed Jan 3, 2019 02:16 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 13,100 | $1.66 | $21,746.00 |
DisclosureSEC source: 0001209191-19-000588 · doc4.xml · nonDerivative · entry 2 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,767 F1 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 29, 2018 Filed Jan 3, 2019 02:16 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 17,667 | $1.66 | $29,327.22 |
DisclosureSEC source: 0001209191-19-000588 · doc4.xml · nonDerivative · entry 1 Lafond Kevin G · CIK 0001429559 · SVP, Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,867 F1 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 21:57 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 9,333 | $4.14 | $38,638.62 |
DisclosureSEC source: 0001209191-18-001005 · doc4.xml · nonDerivative · entry 3 Lafond Kevin G · CIK 0001429559 · Vice Pres., Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,534 F2 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 30, 2017 Filed Jan 3, 2018 21:57 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 13,100 | $4.14 | $54,234.00 |
DisclosureSEC source: 0001209191-18-001005 · doc4.xml · nonDerivative · entry 2 Lafond Kevin G · CIK 0001429559 · Vice Pres., Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,867 F2 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 21:57 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 53,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001005 · doc4.xml · nonDerivative · entry 1 Lafond Kevin G · CIK 0001429559 · Vice Pres., Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,967 F1 · shares: 17,666 shares shall vest on 12/29/2018; 17,667 shares shall vest on each of 12/29/2019 and 12/29/2020. Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 21:41 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 9,333 | $5.35 | $49,931.55 |
DisclosureSEC source: 0001209191-17-001003 · doc4.xml · nonDerivative · entry 2 Lafond Kevin G · CIK 0001429559 · Vice Pres., Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,967 F2 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 21:41 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 39,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-001003 · doc4.xml · nonDerivative · entry 1 Lafond Kevin G · CIK 0001429559 · Vice Pres., Treasurer & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,300 F1 · shares: 13,100 shares shall vest on each of 12/30/2017, 12/30/2018 and 12/30/2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.